I could die for you: new prospects for suicide in gene therapy.

C. Baum

DOI: https://doi.org/10.1038/SJ.MT.6300164

IF: 12.91

2007-05-01

Molecular Therapy

Abstract:

What problem does this paper attempt to address?

Acute exacerbation of idiopathic pulmonary fibrosis model in the rats using bleomycin and lipopolysaccharides

Sandy Vitria Kurniawan,Melva Louisa,Jamal Zaini,Silvia Surini,Vivian Soetikno,Puspita Eka Wuyung,Rosemary Ceria Tatap Uli,Sandy Kurniawan,Puspita Wuyung,Rosemary Uli

DOI: https://doi.org/10.5455/javar.2023.j669

2023-01-01

Journal of Advanced Veterinary and Animal Research

Abstract:Objective: This study was conducted to establish a rat model of acute exacerbation of idiopathic pul¬monary fibrosis (AE-IPF) using the combination of bleomycin (BLM) and lipopolysaccharides (LPS). Materials and Method: Twenty-four male Sprague Dawley rats were allocated into two equal groups: the sham or the bleomycin and lipopolysaccharides-induced AE-IPF group (BLM-LPS). On Day 7, BLM intratracheally and LPS intraperitoneally were both used to administer AE-IPF. The BLM-LPS group and its respective sham group were terminated on Days 8, 14, or 21. Samples of bronchoalveolar lavage fluid (BALF) and lungs were taken and investigated for cell count and histopathology. Results: On Day 8, histological analysis revealed inflammatory cell infiltration with edema and hyaline membrane, and the BALF differential cell count revealed high neutrophil counts. By having a higher collagen density area and Ashcroft modified score than the sham group on Day 14, the BLM-LPS group displayed significantly lower oxygen saturation, alveolar air area, and a fibrotic appearance. However, there was a spontaneous resolution in inflammation and fibrotic appearance on Day 21 after the BLM administration. Conclusions: By combining BLM and LPS, it was possible to create a successful rat model of AE-IPF. The present model showed the peak exacerbation on Day 8 and the fibrotic peak on Day 14, which gradually improved. The optimal time for the new AE-IPF therapeutic intervention was determined to be between Days 8 and 14.
A New Model of Acute Exacerbation of Experimental Pulmonary Fibrosis in Mice

Céline-Hivda Yegen,Liasmine Haine,Kevin Da Costa Ferreira,Dominique Marchant,Jean-Francois Bernaudin,Carole Planès,Nicolas Voituron,Emilie Boncoeur

DOI: https://doi.org/10.3390/cells11213379

IF: 6

2022-10-26

Cells

Abstract:Rationale: idiopathic pulmonary fibrosis (IPF) is the most severe form of fibrosing interstitial lung disease, characterized by progressive respiratory failure leading to death. IPF's natural history is heterogeneous, and its progression unpredictable. Most patients develop a progressive decline of respiratory function over years; some remain stable, but others present a fast-respiratory deterioration without identifiable cause, classified as acute exacerbation (AE). Objectives: to develop and characterize an experimental mice model of lung fibrosis AE, mimicking IPF-AE at the functional, histopathological, cellular and molecular levels. Methods: we established in C57BL/6 male mice a chronic pulmonary fibrosis using a repetitive low-dose bleomycin (BLM) intratracheal (IT) instillation regimen (four instillations of BLM every 2 weeks), followed by two IT instillations of a simple or double-dose BLM challenge to induce AE. Clinical follow-up and histological and molecular analyses were done for fibrotic and inflammatory lung remodeling analysis. Measurements and main results: as compared with a low-dose BLM regimen, this AE model induced a late burst of animal mortality, worsened lung fibrosis and remodeling, and superadded histopathological features as observed in humans IPF-AE. This was associated with stronger inflammation, increased macrophage infiltration of lung tissue and increased levels of pro-inflammatory cytokines in lung homogenates. Finally, it induced in the remodeled lung a diffuse expression of hypoxia-inducible factor 1α, a hallmark of tissular hypoxia response and a major player in the progression of IPF. Conclusion: this new model is a promising model of AE in chronic pulmonary fibrosis that could be relevant to mimic IPF-AE in preclinical trials.
Evaluation of the Inflammatory Response in a Two-Hit Acute Lung Injury Model Using [18F]FDG Micropet

Guang-Ju Zhou,Shou-Yin Jiang,Mao Zhang,Jian-Xin Gan,Guan-Yu Jiang

DOI: https://doi.org/10.3892/etm.2013.1260

2009-01-01

Abstract:The aim of this study was to investigate whether a two-hit acute lung injury (ALI) model is better than a one-hit model in simulating ALI, and to evaluate the inflammatory response in the lungs in these two models using micro-positron emission tomography (microPET) with [18F]fluorodeoxyglucose (FDG). Sprague Dawley rats were divided into four groups; rats in the lipopolysaccharide (LPS; n=10) and LPS-HCl (n=10) groups were challenged by the intraperitoneal administration of 5 mg/kg LPS, while rats in the normal saline (NS; n=3) and HCl (n=10) groups received the same volume of normal saline solution. Sixteen hours following the administration, the rats in the HCl and LPS-HCl groups received an acid instillation (IT) of 0.5 ml/kg HCl (pH=1.2), while the rats in the remaining two groups received the same volume of normal saline solution. The mean arterial blood pressure (MAP) and blood gas concentrations were measured in all four groups. MicroPET was performed 4 h following HCl IT and the lungs were excised for histopathological examination. The rats in the LPS-HCl group exhibited a higher arterial PaO2 and a lower arterial PaCO2 compared with the rats in the remaining groups. The MAP decreased markedly in the LPS-HCl group, but remained stable in the LPS, HCl and NS groups. MicroPET results identified that the region of interest ratio in the LPS-HCl group (9.00±1.41) was significantly higher compared with those in the LPS (4.01±0.60) and HCl (3.33±0.55) groups (P<0.01). In addition, histological examination showed that the mean lung injury score in the LPS-HCl group (12.70±0.95) was significantly higher compared with those in the HCl (8.40±1.26) and LPS (7.00±0.82) groups (P<0.01). The present study demonstrates that LPS pretreatment significantly magnifies and prolongs the inflammatory response to subsequent acid IT in the lungs. Moreover, it is simpler to induce ALI using the two-hit model than with the one-hit model, and [18F]FDG microPET is a useful tool for evaluating the inflammatory reaction during ALI.
Animal models of acute exacerbation of pulmonary fibrosis

Xu Ye,Mingrui Zhang,Huimin Gu,Mengying Liu,Yichao Zhao,Yanchen Shi,Shufei Wu,Cheng Jiang,Xiaoling Ye,Huihui Zhu,Qi Li,Xinmei Huang,Mengshu Cao

DOI: https://doi.org/10.1186/s12931-023-02595-z

IF: 5.8

2023-11-27

Respiratory Research

Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive scarring interstitial lung disease with an unknown cause. Some patients may experience acute exacerbations (AE), which result in severe lung damage visible on imaging or through examination of tissue samples, often leading to high mortality rates. However, the etiology and pathogenesis of AE-IPF remain unclear. AE-IPF patients exhibit diffuse lung damage, apoptosis of type II alveolar epithelial cells, and an excessive inflammatory response. Establishing a reliable animal model of AE is critical for investigating the pathogenesis. Recent studies have reported a variety of animal models for AE-IPF, each with its own advantages and disadvantages. These models are usually established in mice with bleomycin-induced pulmonary fibrosis, using viruses, bacteria, small peptides, or specific drugs. In this review, we present an overview of different AE models, hoping to provide a useful resource for exploring the mechanisms and targeted therapies for AE-IPF.

respiratory system
Bioengineered in Vitro Tissue Model of Fibroblast Activation for Modeling Pulmonary Fibrosis

Aswin Sundarakrishnan,Heather Zukas,Jeannine Coburn,Brian T. Bertini,Zhiyi Liu,Irene Georgakoudi,Lauren Baugh,Queeny Dasgupta,Lauren D. Black,David L. Kaplan

DOI: https://doi.org/10.1021/acsbiomaterials.8b01262

2019-01-01

ACS Biomaterials Science & Engineering

Abstract:Idiopathic pulmonary fibrosis (IPF) is a complex disease of unknown etiology with no current curative treatment. Modeling pulmonary fibrotic (PF) tissue has the potential to improve our understanding of IPF disease progression and treatment. Rodent animal models do not replicate human fibroblastic foci (Hum-FF) pathology, and current iterations of in vitro model systems (e.g., collagen hydrogels, polyacrylamide hydrogels, and fibrosis-on-chip systems) are unable to replicate the three-dimensional (3D) complexity and biochemical composition of human PF tissue. Herein, we fabricated a 3D bioengineered pulmonary fibrotic (Eng-PF) tissue utilizing cell laden silk collagen type I dityrosine cross-linked hydrogels and Flexcell bioreactors. We show that silk collagen type I hydrogels have superior stability and mechanical tunability compared to other hydrogel systems. Using customized Flexcell bioreactors, we reproduced Hum-FF-like pathology with airway epithelial and microvascular endothelial cells. Eng-PF tiss...
Insights into Disease Progression of Translational Preclinical Rat Model of Interstitial Pulmonary Fibrosis through Endpoint Analysis

Anil H. Kadam,Jan E. Schnitzer

DOI: https://doi.org/10.3390/cells13060515

IF: 6

2024-03-15

Cells

Abstract:Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease characterized by the relentless deposition of extracellular matrix (ECM), causing lung distortions and dysfunction. Animal models of human IPF can provide great insight into the mechanistic pathways underlying disease progression and a means for evaluating novel therapeutic approaches. In this study, we describe the effect of bleomycin concentration on disease progression in the classical rat bleomycin model. In a dose–response study (1.5, 2, 2.5 U/kg i.t), we characterized lung fibrosis at day 14 after bleomycin challenge using endpoints including clinical signs, inflammatory cell infiltration, collagen content, and bronchoalveolar lavage fluid-soluble profibrotic mediators. Furthermore, we investigated fibrotic disease progression after 2 U/kg i.t. bleomycin administration at days 3, 7, and 14 by quantifying the expression of clinically relevant signaling molecules and pathways, epithelial mesenchymal transition (EMT) biomarkers, ECM components, and histopathology of the lung. A single bleomycin challenge resulted in a progressive fibrotic response in rat lung tissue over 14 days based on lung collagen content, histopathological changes, and modified Ashcroft score. The early fibrogenesis phase (days 3 to 7) is associated with an increase in profibrotic mediators including TGFβ1, IL6, TNFα, IL1β, CINC1, WISP1, VEGF, and TIMP1. In the mid and late fibrotic stages, the TGFβ/Smad and PDGF/AKT signaling pathways are involved, and clinically relevant proteins targeting galectin-3, LPA1, transglutaminase-2, and lysyl oxidase 2 are upregulated on days 7 and 14. Between days 7 and 14, the expressions of vimentin and α-SMA proteins increase, which is a sign of EMT activation. We confirmed ECM formation by increased expressions of procollagen-1Aα, procollagen-3Aα, fibronectin, and CTGF in the lung on days 7 and 14. Our data provide insights on a complex network of several soluble mediators, clinically relevant signaling pathways, and target proteins that contribute to drive the progressive fibrotic phenotype from the early to late phase (active) in the rat bleomycin model. The framework of endpoints of our study highlights the translational value for pharmacological interventions and mechanistic studies using this model.

cell biology
Establishment of the mouse model of acute exacerbation of idiopathic pulmonary fibrosis

Ya-Ru Wei,Hui Qiu,Qin Wu,Yu-Kui Du,Zhao-Fang Yin,Shan-Shan Chen,Yue-Ping Jin,Meng-Meng Zhao,Chen Wang,Dong Weng,Hui-Ping Li

DOI: https://doi.org/10.3109/01902148.2016.1144835

2016-02-07

Experimental Lung Research

Abstract:PURPOSE: To explore and establish an animal model of AE-IPF.METHODS: An animal model of idiopathic pulmonary fibrosis (IPF) was established using bleomycin (BLM). Then, BLM was administered a second time on day 21 to induce AE-IPF (which mimics human AE-IPF). Evaluation of the success of animal model was based on the survival of mice, as well as assessment of pathological changes in lung tissue. Preliminary investigation into the immunological mechanism of AE-IPF was also explored via the detection and identification of the inflammatory cells in mouse bronchoalveolar lavage fluid (BALF) and the concentrations of six cytokines (IL-4, IL-6, IL-10, IL-17A, MIG, and TGF-β1) in BALF supernatants, which were closely associated with IPF and AE-IPF. The intervention role of IL-17A antibody to AE was explored.RESULTS: By week 4 after the second BLM administration, the mortality in the AE-IPF group was significantly greater (45%, 9/20) than that in stable-IPF group (0/18) (P = .0017). The average body weight in AE-IPF group was significantly lower than that in stable group (P < .0001). In AE-IPF group, inflammation and fibrosis were severer by histopathology analysis. In BALF, IL-17A, MIG (CXCL-9), IL-6, and TGF-β1 levels in AE group were significantly higher. The percentages of neutrophils and Th17 cells in BALF were significantly higher in AE group (P < .01; P = .0281). IL-17A antibody could attenuated the lung inflammation induced by twice BLM challenges.CONCLUSION: A mouse model of AE-IPF can be established using two administrations of BLM; Th17 cells may play a key role during the pathological process of AE-IPF.

respiratory system
Bleomycin mouse model with active-phase pulmonary fibrosis and no acute mortality

ANIL H KADAM,Peggy H. Faix,Jan E. Schnitzer

DOI: https://doi.org/10.21203/rs.2.23139/v1

2020-02-11

Abstract:Abstract Background The bleomycin mouse model is the most prevalent animal model used to study idiopathic pulmonary fibrosis (IPF), ranging from basic pathophysiological mechanisms to therapeutic modalities. High mortality rates, inconsistencies in disease induction, and great severity of the disease phenotype have limited its utility and clinical relevance. In this study, we identify conditions in the mouse bleomycin model that maintain the desired IPF phenotype found in patients while avoiding the usual, associated rapid mouse mortality. Methods In two independent studies, we analyzed the effects of incremental intratracheal (IT) high (1-3 U/kg) and low (0.05-0.5 U/kg) bleomycin doses on pulmonary fibrosis in mice. We observed dose effects on weight loss, morbidity and mortality, inflammation, lung collagen content, presence of various biomarkers in bronchoalveolar lavage fluid (BALf), and histology 14 days post-treatment, when the animals were in the active phase of fibrosis. Results We characterize the fibrotic effects of various bleomycin doses in mice on pulmonary inflammation, myofibroblast activation, vascular leakiness, angiogenesis, and extracellular tissue remodeling. Higher bleomycin doses induced acute disease with severe and saturated responses, extreme and progressive weight loss, and high morbidity and mortality rates. In contrast, lower doses of bleomycin induced a milder and chronic response, featuring robust, active-phase fibrosis with mild weight loss and no mortality. Conclusion Here we demonstrate that the bleomycin mouse model can be used to reproduce symptoms of IPF patients in an animal by using low doses of bleomycin. Low concentrations of bleomycin induce chronic and progressive fibrosis with no mortality.
Investigation of Aberrant Basaloid Cells in a Rat Model of Lung Fibrosis

Emanuela Bocchi,Vanessa Pitozzi,Silvia Pontis,Paola L Caruso,Sofia Beghi,Mariafrancesca Caputi,Marcello Trevisani,Francesca Ruscitti

DOI: https://doi.org/10.31083/j.fbl2908305

2024-08-22

Abstract:Background: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease (ILD) whose cause and pathogenesis are not yet well understood. Until now, no animal model of lung fibrosis succeeds in recapitulating all IPF features, thus the use of different rodent models is essential for the evaluation and development of new effective pharmacological treatments. Recently, the alveolar epithelial dysfunction has been emphasized in the etiopathogenesis context of IPF. Remarkably, the role of an aberrant basaloid cell type, primarily found in humans and confirmed in mice, seems to be crucial in the establishment and progression of the disease/model. Our work aimed to characterize for the first time this cell population in a rat model of lung fibrosis induced by a double bleomycin (BLM) administration, demonstrating the translational value of the model and its potential use in the testing of effective new drugs. Methods: Rats received an intratracheal BLM administration at day 0 and 4. Animals were sacrificed 21 and 28 days post-BLM. The fibrosis evaluation was carried out through histological (Ashcroft score and automatic image analysis) and immunoenzymatic analysis. Immunofluorescence was used for the characterization of the aberrant basaloid cells markers. Results: Lung histology revealed an increase in severe grades of Ashcroft scores and areas of fibrosis, resulting in a rise of collagen deposition at both the analyzed time-points. Immunofluorescence staining indicated the presence of KRT8+ cells in bronchial epithelial cells from both controls (saline, SAL) and BLM-treated animals. Interesting, KRT8+ cells were found exclusively in the fibrotic parenchyma (confirmed by the alpha-smooth muscle actin (α-SMA) staining for myofibroblasts) of BLM-treated animals. Moreover, KRT8+ cells co-expressed markers as Prosurfactant protein C (Pro-SPC) and Vimentin, suggesting their intermediate state potentially originating from alveolar type II (AT2) cells, and participating to the abnormal epithelial-mesenchymal crosstalk. Conclusion: Previous preclinical studies demonstrated the presence of KRT8+ aberrant basaloid-like cells in murine models of lung fibrosis. This work investigated the same cell population in a different rodent (the rat) model of lung fibrosis triggered by a double administration of BLM. Our results provided a further confirmation that, in rats, the intratracheal administration of BLM induced the appearance of a population of cells compatible with the KRT8+ alveolar differentiation intermediate (ADI) cells, as described previously in the mouse. This piece of work enforces previous evidence and further support the use of a rat model of BLM resembling the alveolar epithelial dysfunction to evaluate new clinical candidates for development in IPF.
Modeling of Chronic Lung Inflammation in Rats by Repeated Intratracheal Administration of LPS

V. A. Palikov,Yu. A. Palikova,P. A. Rudenko,V. A. Kazakov,N. A. Borozdina,I. N. Kravchenko,I. A. Pakhomova,E. N. Kazakova,G. A. Slashcheva,S. G. Semushina,O. N. Khokhlova,I. A. Dyachenko

DOI: https://doi.org/10.1007/s10517-022-05633-w

IF: 0.737

2022-11-03

Bulletin of Experimental Biology and Medicine

Abstract:A model of a chronic lung inflammation in SPF Sprague-Dawley rats was developed by repeated intratracheal administration of LPS in a dose of 0.4 mg/kg. On day 22 of the study, male rats treated with LPS have relative monocytopenia and reduced mean concentration of hemoglobin in the erythrocyte and the mean platelet volume in comparison with the control animals (saline). Intratracheal administration of LPS induced an inflammatory process in the lungs characterized by focal atelectasis, compensatory emphysematous expansion of subpleural pulmonary acini, focal mononuclear and neutrophilic perivascular and peribronchial infiltration, and minor focal mononuclear and neutrophilic infiltration of the alveolar walls. Against the background of LPS administration, germinal centers appeared in the lymphoid follicles of the white pulp of the spleen, and focal mononuclear infiltration of the tracheal mucosa and/or submucosa was observed in some animals.

medicine, research & experimental
Pulmonary fibrosis model of mice induced by different administration methods of bleomycin

DOI: https://doi.org/10.1186/s12890-023-02349-z

IF: 3.1

2023-03-22

BMC Pulmonary Medicine

Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease of the lung. How to build a typical human mimicking animal model has been a challenge. Thus, to reveal the mechanism and to make it useful for IPF clinical treatment, a different type of mice model and inspection methods are used to evaluate which one is applicable for the study of IPF.

respiratory system
Establishment of Rat Chronic Obstructive Pulmonary Disease Model with Intratracheal Instillation of Lipopolysaccharide

刘进,吴定钱,童旭峰,管彩虹,沈华浩

DOI: https://doi.org/10.3969/j.issn.1006-2785.2004.04.011

2004-01-01

Abstract:Objective To establish an animal model for chronic obstructive pulmonary disease(COPD).Methods The animal model was established by intratrachel instillation of lipopolysaccharide(LPS)twice and passive smokingfor one month.Pulmonary functions were measured;and the total and different white blood cell counts in peripheral blood and in bronchoalveolar lavage fluid(BALF)were performed.Results In the model animals:the number of goblet cells and the secretion of airway significantly increased than those in controls(P0.01);The histology showed abundant inflammatory cells infiltrating the bronchia walls and lung tissue and the thickened airway walls and the accompanying arterioles with narrowed lumen;It also showed theruptured and enlarged alveoluse;The functional tests showed the increasedairway resistance and the decreased compli-ance of respiratory system;the amount of neutrophils in both BALF and blood increased with positive correla-tion(r=0.581,P0.01).Conclusion The established rat COPD model in this study can be used in experimental research of COPD.[
Comparison of the Results of Modeling Pulmonary Fibrosis in Sprague Dawley Rats by Intratracheal Administration of Bleomycin in the Form of Sulfate and Chloride at a Dose of 3 mg/kg

Elena A. Tukhovskaya,Yulia A. Palikova,Mariya S. Severyukhina,Alina M. Ismailova,Victor A. Palikov,Gulsara A. Slashcheva,Natalya A. Borozdina,Evgeniy S. Mikhaylov,Irina N. Kravchenko,Vitaly A. Kazakov,Ekaterina N. Kazakova,Elena A. Kalabina,Ekaterina A. Rasskazova,Maxim V. Shinelev,Dmitry I. Rzhevsky,Vladimir A. Rykov,Igor A. Dyachenko,Arkady N. Murashev

DOI: https://doi.org/10.3390/ph17101360

IF: 4.6

2024-10-12

Pharmaceuticals

Abstract:Background/Objectives: Intratracheal administration of bleomycin (BLM) to laboratory rodents is a standard, widely used technique used to model pulmonary fibrosis (PF). BLM, as a modeling agent, is produced mainly in the form of two salts—sulfate and chloride. We compared the results of modeling PF in SD rats by intratracheal administration of BLM sulfate and BLM chloride. Methods: Healthy mature male SD rats were used. PF was modeled by intratracheal administration of BLM sulfate and BLM chloride at a dose of 3 mg/kg. The criteria for the development of PF included body weight gain, changes in respiratory parameters, relative lung weight, cellular composition of broncho-alveolar fluid (BALF), histological assessment of the severity of PF with trichrome Masson staining. Results: Intratracheal administration of both BLM salts led to the development of pronounced PF, which was determined by changes in all of the measured parameters relative to control animals. There were no significant differences between the BLM sulfate and BLM chloride groups in body weight gain, hydroxyproline content, and histological evaluation. However, significant differences were identified in the cellular composition of BALF—a significant increase in alveolar macrophages and neutrophils levels in animals treated with BLM sulfate. Conclusions: Intratracheal administration of both BLM salts led to the development of severe PF; however, the inflammatory process in animals receiving BLM sulfate was more pronounced and prolonged than in animals receiving BLM chloride, which in the former, when observed more than 21 days after modeling, can lead to more severe PF.

pharmacology & pharmacy,chemistry, medicinal
[A mouse model of acute lung inflammation induced by lipopolysaccharide inhalation].

Ling Guo,Wen-jing Li,Ming-jiang Xu,Xian Wang

DOI: https://doi.org/10.3969/j.issn.1671-167x.2009.02.022

2009-01-01

Abstract:OBJECTIVE:To develop a convenient, economical and stable model of acute lung inflammation in mice. METHODS:BALB/c mice were inhaled intranasally with 50 microL of LPS (1 g/L) or sterile PBS, and sacrificed at different time points after being anaesthetized. The bronchoalveolar lavage fluid (BALF) was collected, and the lungs were separated and homogenated or embedded and sliced to 5 mum sections, which were then stained by HE to determine the severity of inflammation. The inflammatory cell infiltration in bronchoalveolar lavage was counted and IL-1beta, the pro-inflammatory cytokine, measured by ELISA in lung homogenate and BALF. RESULTS:The data showed that administration with 50 microg of LPS (1 g/L) for 2 h resulted in significant inflammation in the lung. LPS mainly stimulated the recruitment of neutrophils within 24 h. And LPS was a quick revulsant of IL-1beta production in BALF and in lung tissue between 4 and 24 h. Macrophages and lymphocytes recruited after 1 day, and sustained for at least 3 days. CONCLUSION:The results indicate that intranasal administration of LPS can induce a rapid and stable acute inflammatory model in mice.
Establishment of a Rat Model of Chronic Obstructive Pulmonary Disease by Intratracheal Instillation of Lipopolysaccharide

LIU Jun-bo,HUANG Meng-shan,YU Chen-xi,WANG Yan,TANG Fa-di

DOI: https://doi.org/10.3969/j.issn.1005-4847.2011.02.010

2011-01-01

Abstract:Objective To establish and evaluate the feasibility of a rat model of chronic obstructive pulmonary dis-ease(COPD) induced by intratracheal instillation of lipopolysaccharide(LPS).Methods LPS or saline was instilled in-tratracheally in rats once a week for consecutive 8 weeks.The rats were anesthetized and taken for the measurement of lung resistance(RL) and dynamic compliance(Cdyn).Total and differential white blood cell counts in bronchoalveolar lavage fluid(BALF) were carried out.The pathological changes of the lung tissues were observed using HE and AB-PAS stai-ning,and the mucin 5AC content was measured.Results Intratracheal instillation of LPS caused a significant increase in RL(87.5%) and decrease in Cdyn(16.4%).Total and differential white blood cell counts in BALF such as neutrophils,lymphocytes and macrophages were higher in the LPS-treated rats.Chronic bronchitis and emphysematous changes were ob-served as well.Conclusion A typical rat model of COPD can be induced by repeated intratracheal instillation of LPS,show-ing many features of human COPD in the lung function,BALF cytologic and pathologic changes.
SIMULATED AEROMEDICAL EVACUATION EXACERBATES ACUTE LUNG INJURY VIA HYPOXIA-INDUCIBLE FACTOR-1α-MEDIATED BNIP3/NIX-DEPENDENT MITOPHAGY

Chunli Yin,Xinyang Liu,Yujie Ma,Zibo Tang,Wenmin Guo,Bingbing Sun,Jingmei He

DOI: https://doi.org/10.1097/shk.0000000000002306

2024-01-08

Shock

Abstract:ABSTRACT Background With the advancement of medicine and the development of technology, the limiting factors of aeromedical evacuation are gradually decreasing, and the scope of indications is expanding. However, the hypobaric and hypoxic environments experienced by critically ill patients in flight can cause lung injury, leading to inflammation and hypoxemia, which remains one of the few limiting factors for air medical evacuation. This study aimed to examine the mechanism of secondary lung injury in rat models of acute lung injury that simulate aeromedical evacuation. Methods An acute lung injury model was induced in SD rats by the administration of lipopolysaccharide (LPS) followed by exposure to a simulated aeromedical evacuation environment (equivalent to 8,000 feet above sea level) or a normobaric normoxic environment for 4 hours. The expression of hypoxia-inducible transcription-1 α (HIF-1α) was stabilized by pretreatment with dimethyloxalylglycine (DMOG). The reactive oxygen species (ROS) levels and the protein expression levels of HIF-1α, BNIP3 and NIX in lung tissue were measured. Results Simulated aeromedical evacuation exacerbated pathological damage to lung tissue and increased the release of inflammatory cytokines in serum as well as the ROS levels and the protein levels of HIF-1α, BNIP3, and NIX in lung tissue. Pretreatment with DMOG resulted in increases in the protein expression of HIF-1α, BNIP3 and NIX. Conclusion Simulated aeromedical evacuation leads to secondary lung injury through mitophagy.

surgery,peripheral vascular disease,hematology,critical care medicine
The efficacy of teaching dyslexics.

N. Andrews,John Ewart Hardern Shaw

DOI: https://doi.org/10.1111/J.1365-2214.1986.TB00486.X

Abstract:A survey of remedial teaching based on a particular method and carried out in an NHS clinic over 2 years has been presented. The findings suggest a differential pattern of improvement both for reading and spelling as well as for type of learning difficulty, whether 'backward' or 'specifically retarded'. A plea for early recognition of specific learning difficulties and the provision of appropriate remedial teaching is made as the present findings suggest that a structured method of teaching can lead to improvement in both reading and spelling.
[Kinetics and Mechanism in Bleomycin-Induced Murine Pulmonary Fibrosis Model].

Ping Hu,Zhan-cheng Gao

DOI: https://doi.org/10.3760/j.issn:1003-0603.2006.08.008

2006-01-01

Abstract:OBJECTIVETo investigate the kinetics of pathogenesis of bleomycin induced pulmonary fibrosis and its mechanism in mice.METHODSThirty six male ICR mice were randomized as a negative control (NC) group and pulmonary fibrosis model (FM) groups (FMA, FMB, FMC, FMD, FME sub groups). Except for NC group, mice in the other groups were given bleomycin by nasal instillation. Animals in each group were sacrificed on day 6, 14, 21, 28 and 35, respectively. T lymphocytes were quantified for Th1/Th2 and Tc1/Tc2 by flow cytometry. Accumulation of inflammatory cells in bronchioalveolar lavage fluid (BALF) was quantified by cell count. The sections of the right lung were stained with either hematoxylin eosin (HE) or Masson trichrome. The left lung was weighed and its hydroxyproline (HYP) content was assayed. Multi cytokine expression in lung tissue was assayed by semi quantitative reverse transcription polymerase chain reaction (RT-PCR). On day 35, the tidal volume (V(T)), forced expiratory volume in 1 second/forced vital capacity (FEV 0.1/FVC), static compliance (Cst) of mice were determined before they were sacrificed.RESULTS(1)The total cell number in BALF in pulmonary fibrosis groups was statistically significantly higher than that in NC group (all P<0.01), and HYP content in lung tissue in pulmonary fibrosis groups was statistically significantly increased than that in NC group except for group FMA (all P<0.01). (2)V(T) and Cst in FME group were statistically significantly decreased than those in NC group (both P<0.01), and FEV 0.1/FVC was statistically significantly increased (P<0.05). (3)Th1 and Tc1 were demonstrated as the dominant expression in the acute inflammatory stage; Th2 and Tc2 were the dominant expression in the fibrosis forming stage, and then Th1 and Tc1 were again the dominant expression at the terminal stage of pulmonary fibrosis. (4)Compared with the content of cytokine in the lung in NC group, the expression of transforming growth factor-beta1 (TGF-beta1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA were significantly higher in FM groups (all P<0.01).CONCLUSIONThe changes in lung function of bleomycin-induced pulmonary fibrosis in mice are typical of that of restrictive ventilatory disorder. Th2, Tc2 and fibrotic promoting growth factors (TGF-beta1, TIMP-1, etc.) play pivotal roles in the pathogenesis of pulmonary fibrotic process.
Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics

Shuchan Li,Jianrong Shi,Huifang Tang

DOI: https://doi.org/10.1007/s10565-021-09676-z

2021-11-05

Cell Biology and Toxicology

Abstract:Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by progressive loss of pulmonary function. Drug-induced interstitial lung disease has been reported as a severe adverse effect of some drugs, such as bleomycin, amiodarone, and methotrexate. Based on good characteristics, drug-induced pulmonary fibrosis (PF) animal model has played a key role in our understanding of the molecular mechanisms of PF pathogenesis and recapitulates the specific pathology in patients and helps develop therapeutic strategies. Here, we summarize the mechanisms and characteristics of given fibrotic drug-induced animal models for PFs. Together with the key publications describing these models, this brief but detailed overview would be helpful for the pharmacological research with animal models of PFs.Graphical abstractPotential mechanisms underlying drug induced lung toxicity.

cell biology,toxicology
In vivo MRI and PET imaging in a translational ILD mouse model expressing non-resolving fibrosis and bronchiectasis-like pathology after repeated systemic exposure to bleomycin

Irma Mahmutovic Persson,Nina Fransén Petterson,Jian Liu,René in ‘t Zandt,Carla Carvalho,Anders Örbom,Lars E. Olsson,Karin von Wachenfeldt

DOI: https://doi.org/10.3389/fmed.2024.1276420

IF: 3.9

2024-04-09

Frontiers in Medicine

Abstract:Drug-induced interstitial lung disease (ILD) is crucial to detect early to achieve the best treatment outcome. Optimally, non-invasive imaging biomarkers can be used for early detection of disease progression and treatment follow-up. Therefore, reliable in vivo models are warranted in new imaging biomarker development to accelerate better-targeted treatment options. Single-dose bleomycin models have, for a long time, served as a reference model in fibrosis and lung injury research. Here, we aimed to use a clinically more relevant animal model by systemic exposure to bleomycin and assessing disease progression over time by combined magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging. Methods C57BL/6 mice received bleomycin (i.p. 35iU/kg) or saline as control twice per week for 4 weeks. Mice were monitored until 2 weeks after cessation of bleomycin administration (w4 + 1 and w4 + 2), referred to as the resting period. MRI scans were performed in weeks 3 and 4 and during the resting weeks. [ 18 F]FDG-PET was performed at the last week of dosing (w4) and 2 weeks after the last dosing (w4 + 2). Lung tissue sections were stained with Masson’s trichrome and evaluated by modified Ashcroft scoring. Lung volume and lesion volumes were assessed using MRI, as well as 3D mapping of the central airways. Results and discussion Bleomycin-challenged mice showed increased lung weights ( p < 0.05), while total lung volume was unchanged (w4 and onward). Histology analysis demonstrated fibrotic lesions emanating from the distal parts of the lung. Fibrosis progression was visualized by MRI with significantly increased high signal in bleomycin-exposed lungs compared to controls ( p < 0.05). In addition, a significant increase in central airway diameter ( p < 0.01) was displayed in bleomycin-exposed animals compared to controls and further continued to dilate as the disease progressed, comparing the bleomycin groups over time ( p < 0.05–0.001). Lung [ 18 F]FDG uptake was significantly elevated in bleomycin-exposed mice compared to controls ( p < 0.05). Conclusion Non-invasive imaging displayed progressing lesions in the lungs of bleomycin-exposed mice, using two distinct MRI sequences and [ 18 F]FDG-PET. With observed fibrosis progression emanating from distal lung areas, dilation of the central airways was evident. Taken together, this chronic bleomycin-exposure model is translationally more relevant for studying lung injury in ILD and particularly in the context of DIILD.

medicine, general & internal

I could die for you: new prospects for suicide in gene therapy.

Acute exacerbation of idiopathic pulmonary fibrosis model in the rats using bleomycin and lipopolysaccharides

A New Model of Acute Exacerbation of Experimental Pulmonary Fibrosis in Mice

Evaluation of the Inflammatory Response in a Two-Hit Acute Lung Injury Model Using [18F]FDG Micropet

Animal models of acute exacerbation of pulmonary fibrosis

Bioengineered in Vitro Tissue Model of Fibroblast Activation for Modeling Pulmonary Fibrosis

Insights into Disease Progression of Translational Preclinical Rat Model of Interstitial Pulmonary Fibrosis through Endpoint Analysis

Establishment of the mouse model of acute exacerbation of idiopathic pulmonary fibrosis

Bleomycin mouse model with active-phase pulmonary fibrosis and no acute mortality

Investigation of Aberrant Basaloid Cells in a Rat Model of Lung Fibrosis

Modeling of Chronic Lung Inflammation in Rats by Repeated Intratracheal Administration of LPS

Pulmonary fibrosis model of mice induced by different administration methods of bleomycin

Establishment of Rat Chronic Obstructive Pulmonary Disease Model with Intratracheal Instillation of Lipopolysaccharide

Comparison of the Results of Modeling Pulmonary Fibrosis in Sprague Dawley Rats by Intratracheal Administration of Bleomycin in the Form of Sulfate and Chloride at a Dose of 3 mg/kg

[A mouse model of acute lung inflammation induced by lipopolysaccharide inhalation].

Establishment of a Rat Model of Chronic Obstructive Pulmonary Disease by Intratracheal Instillation of Lipopolysaccharide

SIMULATED AEROMEDICAL EVACUATION EXACERBATES ACUTE LUNG INJURY VIA HYPOXIA-INDUCIBLE FACTOR-1α-MEDIATED BNIP3/NIX-DEPENDENT MITOPHAGY

The efficacy of teaching dyslexics.

[Kinetics and Mechanism in Bleomycin-Induced Murine Pulmonary Fibrosis Model].

Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics

In vivo MRI and PET imaging in a translational ILD mouse model expressing non-resolving fibrosis and bronchiectasis-like pathology after repeated systemic exposure to bleomycin